Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity

摘要

The present invention relates to the use of reversible selective inhibitors of monoamine oxydase A (MAO-A), reversible selective inhibitors of monoamine oxydase B (MAO-B) or reversible mixed inhibitors of monoamine oxydase A and B (MAO-A and MAO-B) in the manufacture of drugs intended for the treatment of obesity: more specifically, the inhibitors are 3(S),3a(S)­-3-methoxymethyl-7- 4,4,4-trifluorobutoxy­-3,3a,4,5-tetrahydro-1H-oxazolo 3,4-a­quinolin-1-one, (R)-5-(methoxymethyl)-3- 6-(4,4,4-trifluorobutoxy)benzofuran-3-yl­oxazolidin-2-one and (R)-5-methoxymethyl-3-(6-cyclopropylmethoxybenzofuran-3-yl)oxazolidin- 2-one, (S)-5-methoxymethyl-3- 6-(4,4,4-trifluorobutoxy)-1,2-benzisoxazol-3-yl­oxazolidin-2-one, lazabemide, milacemide, caroxazone, IFO, befloxatone, moclobemide, brofaromine, phenoxathine, esuprone, befol, RS 8359 (Sankyo), T794 (Tanabe), KP 9 (Krenitsky, USA), E 2011 (Eisei), toloxatone, pirlindole, amiflamine, sercloremine and bazinaprine. The examples give befloxatone.